Cogent Biosciences (COGT) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

COGT Cogent Biosciences

Watchlist

9.060
-0.020-0.22%

Trading Nov 21 15:26 ET

1.00BMarket Cap-3653P/E (TTM)

Intraday

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Express News | Cogent Biosciences Inc : Guggenheim Cuts Target Price to $17 From $20
ReutersNov 18 06:29 ET
J.P. Morgan Maintains Cogent Biosciences(COGT.US) With Buy Rating, Raises Target Price to $21
Moomoo NewsNov 14 07:31 ET · Ratings
Cogent Biosciences Is Maintained at Buy by Needham
Dow JonesNov 13 05:46 ET · Ratings
Needham Maintains Cogent Biosciences(COGT.US) With Buy Rating, Cuts Target Price to $15
Moomoo NewsNov 13 05:38 ET · Ratings
Express News | Cogent Biosciences Inc : Needham Cuts Target Price to $15 From $16
ReutersNov 13 05:28 ET
Cogent Biosciences: Buy Rating Affirmed Amid Anticipation for Bezuclastinib Data and Strong Financial Position
TipRanksNov 13 05:27 ET · Ratings

Comments

Trytosaveabit

Jun 14 06:37

Update

$Cogent Biosciences (COGT.US)$ Reuters· 3 mins ago
Cogent Biosciences Inc: Summit Trial Showed Clinically Meaningful Improvement in Skin Symptoms as Well as Objective Reduction in Skin Lesions

Trytosaveabit

May 23 17:03

Even better!

$Cogent Biosciences (COGT.US)$ Cogent Biosciences (COGT) said Thursday that new lead-in data from ongoing phase 3 trial of a combination of bezuclastinib and sunitinib showed potential to become new standard of care for advanced gastrointestinal stromal tumors, a type of cancer.
The company said the combination treatment led to a disease control rate of 80% in all patients and 100% in patients that were previously treated with imatinib only.
"Coupled with the impressive clinical activ...

Trytosaveabit

May 23 16:12

Update

$Cogent Biosciences (COGT.US)$ Cogent Biosciences Reports Updated Lead-In Data From Ongoing Phase 3 PEAK Trial At ASCO Annual Meeting
Addition of Bezuclastinib to Sunitinib Continues to Be Generally Well-Tolerated With an Encouraging Safety Profile

Stock Region

Feb 23 10:35

Positive 1b Data For Mastocytosis Therapy Announced By Major Biotech Company

Cogent Biosciences Unveils Positive Data from SUMMIT Trial of Bezuclastinib in Nonadvanced Systemic Mastocytosis Patients.
In a significant development for the biotech industry, Cogent Biosciences has announced positive Part 1b data from its SUMMIT trial evaluating Bezuclastinib, a novel targeted therapy, in patients with nonadvanced systemic mastocytosis (SM). The news marks a major milestone in the ongoing efforts to d...

Trytosaveabit

Feb 22 14:01

Sorry a bit late! Grrrr! Was busy! Grrrr

$Cogent Biosciences (COGT.US)$ Cogent Biosciences Announces Positive Part 1b Data From SUMMIT Trial Evaluating Bezuclastinib in Patients With Nonadvanced Systemic Mastocytosis
GlobeNewswire· 30 mins ago

Analyst Rating

No Data

Price Target

No Data

Heat List

Overall

No Data

COGT Cogent Biosciences

Trade Overview

Capital Trend

News

Comments

Analysis

Analyst Rating

Price Target